View Letter

Dear Chairwoman Murray, Chairwoman DeLauro, and Ranking Members Blunt and Cole:

As you and your colleagues work on the Fiscal Year (FY) 2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bill, we respectfully request that you increase funding for the U.S. Centers for Disease Control and Prevention (CDC) to continue its efforts to harmonize the reporting of clinical laboratory test results after funding the program in FY’21.

The undersigned organizations believe that every patient should have access to dependable and accurate clinical laboratory test results and that those test results should be harmonized. The CDC is doing incredible work harmonizing the results for several tests, and we believe with continued funding CDC could expand its efforts—benefiting clinicians and patients alike and contributing to overall efficiencies in public health and healthcare.

Clinical laboratory testing plays an important role in medical decision-making. As the healthcare delivery system moves towards a more integrated model where health information will be shared amongst providers, patients, and payers, laboratory data will be the key piece of health information that will be used to improve the quality of care using clinical guidelines, performance measures, and electronic health records. For most laboratory tests, however, a gold standard either does not exist or is not readily applied. Unfortunately, this means that a result from one clinical test method may present a different numeric value compared to another clinical test method measuring the same patient sample, even though each result is accurate within the context of its own method. Experts call this a lack of harmonization. A test that is harmonized (or standardized) provides the same result regardless of the method or instrument used or the setting where it is performed.

Congress has showed its support for CDC’s harmonization efforts over the last several years and CDC has responded by producing several breakthroughs. Past funding has resulted in expanded harmonization and standardization activities that improve detection and management of hormone disorders, kidney disease, cancer, and heart disease. Specific examples of CDC’s progress include:

  • Producing and distributing reference/harmonization materials for clinical standardization programs and to 30 countries for chronic disease biomarkers
  • Developing reference methods for highly accurate measurement of biomarkers used for the diagnosis of multiple diseases, including bone, kidney, diabetes, cardiovascular, endocrine and cancers
  • Expanding outreach of harmonization/standardization programming to non-traditional markers, point-of-care-testing devices and patient and payor organizations.
  • Conducting method performance evaluations for laboratories/manufacturers and issuing performance certificates.

In just a few short years, CDC has managed to make great strides in this area. To continue this advancement, we recommend that for FY 2022 the CDC be appropriated an additional $7.2 million for activities directed by its Environment Health Laboratory. We believe this continued investment in CDC will lead to future cost savings and better health outcomes. The undersigned groups stand ready to be an ongoing resource to members of Congress on laboratory testing harmonization and we appreciate your consideration.

Sincerely yours,

American Association for Clinical Chemistry

American Clinical Laboratory Association

American Medical Technologists

American Society for Clinical Laboratory Science

American Society for Clinical Pathology

American Urological Association

ARUP Laboratories

Association of Public Health Laboratories

Clinical Laboratory Management Association


College of American Pathologists

Endocrine Society

Laboratory Corporation of America Holdings

Mayo Medical Laboratories

PCOS Challenge: The National Polycystic Ovary Syndrome Association

Pediatric Endocrine Society

Quest Diagnostics

Roche Diagnostics

Siemens Healthineers

Society for Reproductive Investigation

Thermo Fisher Scientific